Statistics from Altmetric.com
I thank Archives of Disease in Childhood for affording me the right of reply to the letter by Hall et al.1 As always, when given this courtesy, it is hard to know whether first to rebut my detractors’ final statement and work backwards or to begin from the top. Assuming that you’ve just read their challenge – and haven’t already yourself fallen for the appeal of the Response button – I’ll deal with the school entry issue first.
As all the signatories must know, even an accurate single growth screen at school entry is virtually worthless since it will confirm only how tall, short, fat or thin the child is on the day the child is measured. The Coventry Consensus was, therefore, wrong not to recommend an appropriate second or third measurement to establish the trend, and the many people who disagreed with the single check decision (see below) were right. Unfortunately, they didn’t insist enough that the staffing …
Competing interests: Under an agreement with the UK Charities Commission, Novo Nordisk UK (who make growth hormone therapies) fund a proportion of Mr Fry's salary so that he can run the Child Growth Foundation (CGF) full time—he receives no direct financial support from the CGF. The foundation receives ad hoc fees from a number of drug companies who buy the auxology training course. In addition, CGF manages certain research projects for clinicians that are funded by drug companies (CGF receives no management fee but profits from the bank interest accrued while the research is being conducted).
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.